Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III purchased 50,000 shares of Xencor stock in a transaction on Thursday, November 2nd. The shares were acquired at an average price of $19.58 per share, for a total transaction of $979,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Shares of Xencor, Inc. (NASDAQ XNCR) traded up $0.88 during trading on Friday, hitting $20.21. 104,809 shares of the stock traded hands, compared to its average volume of 169,708.
Xencor (NASDAQ:XNCR) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.10. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. The firm had revenue of $13.34 million for the quarter, compared to analysts’ expectations of $8.15 million. equities analysts forecast that Xencor, Inc. will post -1.07 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2017/11/03/xencor-inc-xncr-major-shareholder-john-s-stafford-iii-acquires-50000-shares.html.
Hedge funds have recently made changes to their positions in the stock. Equitec Specialists LLC purchased a new stake in Xencor in the second quarter worth $116,000. SG Americas Securities LLC lifted its stake in Xencor by 62.6% in the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock worth $178,000 after acquiring an additional 3,252 shares during the period. Principal Financial Group Inc. purchased a new stake in Xencor in the third quarter worth $201,000. Legal & General Group Plc lifted its stake in Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 385 shares during the period. Finally, Citadel Advisors LLC purchased a new stake in Xencor in the second quarter worth $224,000. 76.81% of the stock is owned by institutional investors.
A number of research analysts have commented on XNCR shares. ValuEngine cut shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. Canaccord Genuity set a $36.00 price target on shares of Xencor and gave the company a “buy” rating in a research report on Monday, October 23rd. BidaskClub cut shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Finally, Zacks Investment Research cut shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. Xencor currently has an average rating of “Hold” and a consensus price target of $28.00.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
What are top analysts saying about Xencor Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Xencor Inc. and related companies.